{
"id":"mk19_b_gm_s7",
"subspecialtyId":"gm2",
"title":"Women's Health",
"jsonContent":{
"type":"section",
"id":"mk19_b_gm_s7",
"title":{
"__html":"Women's Health"
},
"titleNode":{
"type":"section-title",
"hlId":"174236",
"children":[
"Women's Health"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_1",
"title":{
"__html":"Breast Symptoms"
},
"titleNode":{
"type":"section-title",
"hlId":"5d21c8",
"children":[
"Breast Symptoms"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_1_1",
"title":{
"__html":"Breast Mass"
},
"titleNode":{
"type":"section-title",
"hlId":"dc2a65",
"children":[
"Breast Mass"
]
},
"children":[
{
"type":"p",
"hlId":"b72885",
"children":[
"A palpable breast mass warrants evaluation in all women. Although breast cancer should be considered in all patients, most breast masses, particularly in women younger than 30 years, are benign conditions, such as cysts, fibroadenomas, fat necrosis, or lipomas."
]
},
{
"type":"p",
"hlId":"5b9518",
"children":[
"Evaluation requires consideration of breast cancer risk factors, including family history of breast or ovarian cancer, previous breast biopsies, hormonal risk factors, and breast density, and a detailed history of the mass, including onset, changes with the menstrual cycle, associated symptoms, and changes in the overlying skin or nipples."
]
},
{
"type":"p",
"hlId":"484a30",
"children":[
"A clinical breast examination (CBE) should be performed in all women presenting with a breast mass and includes visual inspection, with attention to any skin changes; palpation of the breast; and palpation of the axillary, supraclavicular, and cervical lymph nodes. Findings on CBE may suggest a benign (smooth, mobile, regular) or a malignant (fixed, hard, heterogeneous) process. However, the predictive value of CBE is poor, and all women require further evaluation with imaging and/or biopsy."
]
},
{
"type":"p",
"hlId":"f7f7ea",
"children":[
"Imaging of a breast mass may include diagnostic mammography and targeted ultrasonography of the mass. Mammography is the first test performed in most women aged 30 years or older. The mammogram may demonstrate a mass, asymmetric density, or abnormal or pleomorphic calcifications potentially indicating breast cancer (see ",
{
"type":"cross-reference",
"target":"mk19_a_on_s2_3",
"children":[
"MKSAP 19 Oncology"
]
},
"). For patients with a focal abnormality on clinical examination or mammography, targeted ultrasonography can clarify the size of the mass, determine whether the mass is solid or cystic, and identify the margins as smooth or irregular. Ultrasonography is the preferred method of evaluation for women younger than 30 years, in whom mammography has low sensitivity owing to dense breasts. It is also the test of choice in pregnant patients. When breast imaging is completed, results are categorized by using the Breast Imaging Reporting and Data System (BI-RADS) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t46",
"wrapId":"1",
"children":[
"Table 46"
]
}
]
},
")"
]
},
". Biopsy is recommended for category 4 and 5 breast findings. Regardless of the BI-RADS category, any suspicious finding on CBE should be evaluated by biopsy, even if no mass is identified on imaging."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_gm_t46"
]
},
{
"type":"p",
"hlId":"0b099d",
"children":[
"In most cases, if a woman requires a biopsy, an image-guided core-needle biopsy is the most appropriate choice. It is important to always perform imaging before biopsy because biopsy can distort the tissue. For cystic lesions, fine-needle aspiration may be appropriate for a simple cyst; however, if imaging is convincing for a benign process, aspiration may not be required. Any complex cyst that is BI-RADS category 4 or higher should be biopsied rather than aspirated. Management of an abnormal finding requires consultation with a breast surgeon. A surgical biopsy is performed when the core-needle biopsy is technically challenging owing to location of the lesion, when atypical hyperplasia is seen on core-needle biopsy specimens, or when the pathology and imaging findings are discordant."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_1_2",
"title":{
"__html":"Breast Pain"
},
"titleNode":{
"type":"section-title",
"hlId":"0f18cb",
"children":[
"Breast Pain"
]
},
"children":[
{
"type":"p",
"hlId":"2a1bf8",
"children":[
"Breast pain (mastalgia) is common and may be cyclic or noncyclic in relation to the menstrual cycle. Cyclic breast pain is most common in women aged 20 to 39 years. The pain is often diffuse and bilateral, occurs during the premenstrual phase, and resolves with onset of menstruation; it is usually associated with hormonal changes and is typically benign. Noncyclic breast pain is often caused by medication use (contraceptive agents, hormone replacement therapy, psychiatric medications), underlying breast disease (fibrocystic disease, infection, trauma, cancer), or stretching of the Cooper ligaments (connective tissue that maintains breast structural integrity). Nonbreast causes of breast pain include costochondritis, trauma, coronary artery disease, gastroesophageal reflux disease, and intercostal nerve pain."
]
},
{
"type":"p",
"hlId":"7c2bc8",
"children":[
"Evaluation of breast pain includes a detailed history to identify characteristics of the pain and its relationship to menses as well as a CBE. Women evaluated for breast pain with no obvious abnormal findings should be up to date with routine age- and risk-appropriate breast screening. Women with cyclical pain and a normal CBE do not require additional imaging. Patients with noncyclic focal mastalgia who are younger than 30 years should be evaluated with breast ultrasonography, whereas patients older than 30 years should undergo diagnostic mammography and breast ultrasonography. Any palpable breast mass should be evaluated with diagnostic imaging (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_1_1",
"children":[
"Breast Mass"
]
},
")."
]
},
{
"type":"p",
"hlId":"2c8a9d",
"children":[
"For women with cyclic breast pain and negative clinical findings, conservative management (education, reassurance of the absence of malignancy, advice to wear a supportive and well-fitting brassiere, and topical NSAID therapy) is recommended because cyclic pain usually resolves spontaneously. Evidence is lacking to support limiting caffeine intake or using vitamin E as a means of mitigating the pain. Medical management may be offered for patients with severe pain that persists despite conservative management. Danazol is the only FDA-approved agent for cyclic breast pain, but its use is limited by side effects, including amenorrhea, hirsutism, and adverse changes in the lipid profile. Low-dose tamoxifen, although not FDA approved for this indication, has been shown to have benefit with fewer side effects; however, hot flashes, vaginal dryness, venous thromboembolism, and teratogenicity must be considered. Treatment of noncyclic breast pain depends on the underlying cause."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_1_3",
"title":{
"__html":"Mastitis"
},
"titleNode":{
"type":"section-title",
"hlId":"c586ca",
"children":[
"Mastitis"
]
},
"children":[
{
"type":"p",
"hlId":"a02906",
"children":[
"Mastitis refers to inflammation of the breast tissue, which usually occurs in the presence of lactation. Lactational mastitis is secondary to milk stasis. It usually occurs within the first 3 months of lactation and presents with redness, warmth, and swelling of the breast. Initial treatment focuses on NSAIDs, cold compresses, and, most importantly, complete breast emptying. Infection may result, and antibiotics should be given if symptoms are severe at presentation or persist after 12 to 24 hours of breast drainage. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" is the most common cause, and cephalexin or dicloxacillin are used in the absence of methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"S. aureus"
]
},
" risk factors. Therapy may be directed by the results of breast milk culture and ultrasonography performed if abscess is suspected."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_1_4",
"title":{
"__html":"Nipple Discharge"
},
"titleNode":{
"type":"section-title",
"hlId":"4fef77",
"children":[
"Nipple Discharge"
]
},
"children":[
{
"type":"p",
"hlId":"397b4a",
"children":[
"Nipple discharge most commonly results from physiologic causes (galactorrhea), but it may also be associated with malignancy and evaluation is always necessary. Galactorrhea is characterized by discharge that is bilateral, emanates from multiple ductal openings, and may occur with breast movement. Pregnancy is the most common cause, but thyroid disease and hyperprolactinemia may also be causative. Testing includes a pregnancy test, thyroid-stimulating hormone level, and prolactin level."
]
},
{
"type":"p",
"hlId":"a8fac6",
"children":[
"Nipple discharge that is unilateral, bloody, occurs without breast movement, or in a woman older than age 40 years raises concern for a pathologic cause, including intraductal papilloma and breast cancer. Evaluation is guided by patient age. In patients older than age 40, both mammography and breast ultrasonography should be completed, whereas in patients aged 30 to 39 years mammography alone is appropriate unless there are abnormalities noted. In patients younger than age 30, ultrasonography is the first-line test."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"657bd3",
"children":[
"Mammography is the first test performed in most women aged 30 years or older with a breast mass."
]
},
{
"type":"keypoint",
"hlId":"03ee64",
"hvc":true,
"children":[
"Ultrasonography is the preferred method of evaluation of a breast mass in women younger than 30 years."
]
},
{
"type":"keypoint",
"hlId":"4cd003",
"children":[
"A suspicious breast mass should be evaluated with a biopsy even if imaging results are negative."
]
},
{
"type":"keypoint",
"hlId":"b14ca3",
"hvc":true,
"children":[
"Cyclic breast pain often occurs in the premenstrual phase, tends to be bilateral, and resolves with onset of menstruation and conservative management."
]
},
{
"type":"keypoint",
"hlId":"3a43d0",
"children":[
"Noncyclic breast pain is usually related to underlying breast conditions; patients with noncyclic focal breast pain should be evaluated with age-appropriate imaging."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2",
"title":{
"__html":"Reproductive Health"
},
"titleNode":{
"type":"section-title",
"hlId":"aad780",
"children":[
"Reproductive Health"
]
},
"children":[
{
"type":"p",
"hlId":"5fd744",
"children":[
"The Centers for Disease Control and Prevention provides information and recommendations on reproductive health (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/reproductivehealth/index.html",
"target":"_blank"
},
"children":[
"www.cdc.gov/reproductivehealth/index.html"
]
},
")."
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1",
"title":{
"__html":"Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"5ed336",
"children":[
"Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"019470",
"children":[
"Approximately 45% of pregnancies in the United States are unintended; the incidence is higher among women of low socioeconomic status and is a marker of reproductive health care disparities. Contraception should be offered to all women of reproductive potential, particularly those with medical conditions that increase risk for pregnancy. Contraception safety based on a woman's individual medical comorbidities can be assessed using the CDC Medical Eligibility Criteria (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html",
"target":"_blank"
},
"children":[
"www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html"
]
},
")."
]
},
{
"type":"p",
"hlId":"ef27c9",
"children":[
"Contraceptive options include reversible and permanent methods. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t47",
"wrapId":"2",
"children":[
"Table 47"
]
}
]
},
" provides a comparison of contraceptive options."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_gm_t47"
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_1",
"title":{
"__html":"Hormonal Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"143416",
"children":[
"Hormonal Contraception"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_1_1",
"title":{
"__html":"Combined Hormonal Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"9bbc8d",
"children":[
"Combined Hormonal Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"b8c86f",
"children":[
"Combined hormonal (estrogen-progesterone) contraception (CHC) includes oral contraceptive pills, the transdermal patch, and the vaginal ring. The use of CHC is associated with a decreased risk for endometrial and ovarian cancer and is an effective treatment for menorrhagia and dysmenorrhea. CHCs are associated with a small increased risk for venous thromboembolism (VTE). Contraindications to estrogen-progesterone contraceptives include breast cancer, VTE, uncontrolled hypertension, liver disease, migraine with aura, and smoking more than 15 cigarettes a day for women older than 35 years."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_1_2",
"title":{
"__html":"Progesterone-Only Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"3d7477",
"children":[
"Progesterone-Only Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"14eb30",
"children":[
"Progesterone-only contraception includes a daily oral pill; depot medroxyprogesterone acetate injection, which is administered every 3 months; and the subdermal implant. All methods work by thickening cervical mucus and inhibiting ovulation. There is no increased risk for VTE with progestin-only contraception."
]
},
{
"type":"p",
"hlId":"647394",
"children":[
"The progestin-based subdermal implant is placed in the arm and is approved for 3 years of use. It is the most effective contraceptive option, with a failure rate below 0.05% at 1 year. It is well tolerated but may cause irregular vaginal bleeding; there is a small risk for infection or hematoma with both insertion and removal."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_1_3",
"title":{
"__html":"Long-Acting Reversible Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"def368",
"children":[
"Long-Acting Reversible Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"6e8223",
"children":[
"Long-acting reversible contraceptives are highly effective and include intrauterine devices (IUDs) and subdermal implants (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_2_1_1_2",
"children":[
"Progesterone-Only Contraception"
]
},
"). An IUD is a small, T-shaped device placed inside the uterus. There are five FDA-approved IUDs, including one copper device and four levonorgestrel-releasing (LNG-IUD) devices. Both types work by preventing fertilization and implantation. The copper IUD releases copper ions, which are toxic to sperm; it is FDA approved for up to 10 years of use. The LNG-IUD inhibits ovulation and thickens cervical mucus, obstructing sperm penetration; it is FDA approved for 3 to 5 years of use, depending on the brand. It is also highly effective at treating menorrhagia."
]
},
{
"type":"p",
"hlId":"9ba002",
"children":[
"Changes in menstrual bleeding patterns are the most common adverse effect. Complications include expulsion (3%-6% in the first year) and uterine perforation (approximately 0.1% of insertions). Risk for pelvic infection with IUD placement is low, and prophylactic antibiotics are not recommended during the procedure. If a sexually transmitted infection (STI) occurs with an IUD in place, the IUD does not need to be removed. Contraindications to IUD placement include pregnancy, anatomic uterine abnormalities with distortion of the uterine cavity, and acute untreated pelvic infection."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_2",
"title":{
"__html":"Barrier Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"2b9b71",
"children":[
"Barrier Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"7272b2",
"children":[
"Barrier contraceptive methods, such as diaphragms and condoms, are among the least effective of all the modes of contraception. Their efficacy is improved when combined with a spermicidal agent. Use of either male or female condoms reduces the risk for STIs. However, the use of spermicide may increase risk for HIV transmission by disrupting the vaginal epithelial wall."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_3",
"title":{
"__html":"Permanent Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"5632f8",
"children":[
"Permanent Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"2bb738",
"children":[
"There are several methods of female sterilization. Options include salpingectomy and clipping or electrosurgical desiccation of the fallopian tubes; salpingectomy may be associated with a decreased risk for ovarian cancer. Women who are considering sterilization should be counseled regarding procedural risk, the permanency of the method, and the availability of alternative long-acting reversible contraceptive methods."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_1_4",
"title":{
"__html":"Emergency Contraception"
},
"titleNode":{
"type":"section-title",
"hlId":"5e2677",
"children":[
"Emergency Contraception"
]
},
"children":[
{
"type":"p",
"hlId":"6bd35e",
"children":[
"Emergency contraception is contraception using a device or medication to prevent pregnancy after inadequately protected intercourse. The most effective form of emergency contraception is the placement of a copper IUD within 5 days of intercourse, which can reduce the risk for pregnancy by 99%. Recent data indicate that the 52-mg LNG-IUD is noninferior to the copper IUD for emergency contraception; however, it is not currently approved for this indication. Two oral contraceptive options are ulipristal acetate and levonorgestrel. Ulipristal acetate requires a prescription and is effective for up to 5 days after unprotected intercourse. Levonorgestrel is available over the counter and is effective in the 3 days after intercourse. It is less effective in overweight women, and women with a BMI greater than 26 should use either the copper IUD or ulipristal acetate."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_2",
"title":{
"__html":"Preconception Care"
},
"titleNode":{
"type":"section-title",
"hlId":"9def54",
"children":[
"Preconception Care"
]
},
"children":[
{
"type":"p",
"hlId":"f60432",
"children":[
"Preconception counseling refers to education provided before pregnancy, aimed at ensuring a healthy pregnancy and reducing the risk for preterm birth and congenital anomalies. This differs from prenatal counseling, which occurs after pregnancy is diagnosed."
]
},
{
"type":"p",
"hlId":"37cfdd",
"children":[
"Any primary care visit for a woman of reproductive age is an opportunity to routinely ask whether she would like to become pregnant in the next year. Women who are not interested in pregnancy should be offered contraception. For women considering pregnancy, a comprehensive risk assessment should be completed ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t48",
"wrapId":"3",
"children":[
"Table 48"
]
}
]
},
")"
]
},
". An obstetric history of gestational hypertension, preeclampsia, or gestational diabetes is particularly predictive of future risk. Women at increased risk for preeclampsia should be counseled about the use of low-dose aspirin in pregnancy for prevention."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_gm_t48"
]
},
{
"type":"p",
"hlId":"250c10",
"children":[
"All medications should be reviewed for potential teratogens ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t49",
"wrapId":"4",
"children":[
"Table 49"
]
}
]
},
")"
]
},
". In 2015, the FDA published changes in pregnancy and lactation labeling for prescription drugs and discontinued use of the previous letter system for categorizing risk. Labeling now includes information relevant to the use of the drug in pregnant and lactating women as well as information regarding potential risks to females and males of reproductive potential."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_gm_t49"
]
},
{
"type":"p",
"hlId":"48b201",
"children":[
"Physical examination includes assessment of blood pressure and BMI. Pelvic examination may be indicated if a woman is due for cervical cancer screening or is experiencing vaginal symptoms. HIV counseling and screening are recommended for all women planning pregnancy."
]
},
{
"type":"p",
"hlId":"9035df",
"children":[
"Intervention to prevent complications depends on the risk assessment. All women should be encouraged to follow a healthy lifestyle, with emphasis on complete cessation of tobacco, alcohol, marijuana, or illicit drugs before conception. In addition, they should be encouraged to attain a normal BMI before conception."
]
},
{
"type":"p",
"hlId":"34fc60",
"children":[
"Women should be up to date with immunizations. Women who are considering pregnancy should be assessed for immunity to varicella and rubella. For women who are not immune, varicella and rubella vaccination should be done, with the advice that pregnancy be avoided for at least 4 weeks after the vaccine is administered to reduce risk to the fetus. Immunizations to be avoided during pregnancy include live vaccines (varicella, rubella, measles, mumps, live attenuated influenza, live attenuated herpes zoster) and human papillomavirus vaccine."
]
},
{
"type":"p",
"hlId":"e3f3fa",
"children":[
"Patients at potential risk for exposure to infectious diseases, such as Zika virus, should be counseled regarding travel restrictions, mode of transmission (including mosquito bites, sexual intercourse, and blood transfusion), and timing of pregnancy after travel. The CDC maintains up-to-date information regarding Zika virus and pregnancy (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/zika/pregnancy/index.html",
"target":"_blank"
},
"children":[
"www.cdc.gov/zika/pregnancy/index.html"
]
},
")."
]
},
{
"type":"p",
"hlId":"3c2699",
"children":[
"Consultation with a genetics counselor may be helpful if there is a personal or family history of genetic disorders."
]
},
{
"type":"p",
"hlId":"4c2b03",
"children":[
"Interventions that optimize pregnancy outcomes include folic acid supplementation (0.4-0.8 mg/d [400-800 µg/d]) to reduce the risk for neural tube defects. Low-dose oral iron supplements can reduce the risk for maternal anemia. Prenatal multivitamins that contain sufficient folic acid are a reasonable option for women contemplating pregnancy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_2_3",
"title":{
"__html":"Postpartum Care"
},
"titleNode":{
"type":"section-title",
"hlId":"78f049",
"children":[
"Postpartum Care"
]
},
"children":[
{
"type":"p",
"hlId":"41b09e",
"children":[
"The rise in maternal mortality in the United States over the past two decades and a shift in etiology of maternal death, from obstetric complications to cardiovascular disease, has increased the emphasis on high-quality postpartum care for women. The postpartum period begins after birth and extends up to 1 year thereafter. Although women should ideally see their obstetric provider within 12 weeks after delivery, up to 40% of women do not attend their immediate postpartum visit."
]
},
{
"type":"p",
"hlId":"3e8459",
"children":[
"In the postpartum period, women should have a comprehensive evaluation that involves the assessment of several health domains ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t50",
"wrapId":"5",
"children":[
"Table 50"
]
}
]
},
")"
]
},
". Immediately after birth, postpartum women are at increased risk for multiple health issues, including preeclampsia/eclampsia; VTE; postpartum depression; urinary incontinence; and breastfeeding complications, such as mastitis. The postpartum period is also an opportunity to assess sexual health and contraceptive needs. Birth spacing, with an interval of at least 6 months and ideally more than 18 months between birth and the next pregnancy, is associated with fewer adverse outcomes and should be discussed. Thyroid disease, including hyper- and hypothyroidism, is common in the year after delivery. Women with a history of postpartum thyroiditis should be screened with serum thyroid-stimulating hormone (TSH) measurement at 3 and 6 months postpartum and then annually."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_gm_t50"
]
},
{
"type":"p",
"hlId":"a3ada3",
"children":[
"Women with pregnancy complications, such as gestational diabetes and hypertensive disorders of pregnancy, have an increased long-term risk for diabetes and cardiovascular disease. Women with gestational diabetes require screening with either a fasting blood glucose level or a 2-hour, 75-g oral glucose tolerance test between 6 and 12 weeks postpartum and then screening every 1 to 3 years with a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" level. There are currently no guidelines for management of women with hypertensive disorders of pregnancy. Women with gestational diabetes and hypertensive disorders of pregnancy should be counseled on risk mitigation, including the importance of a healthy lifestyle and achieving a healthy postpartum weight. In addition, they should be monitored closely for the development of diabetes and cardiovascular disease, with aggressive management of blood pressure to prevent future disease."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"801a5e",
"children":[
"Contraception should be offered to all women of reproductive potential, particularly those with medical conditions that increase risk for pregnancy."
]
},
{
"type":"keypoint",
"hlId":"0bc97a",
"children":[
"Contraindications to combination estrogen-progesterone contraceptives include breast cancer, venous thromboembolism, uncontrolled hypertension, liver disease, migraine with aura, and smoking more than 15 cigarettes a day for women older than 35 years."
]
},
{
"type":"keypoint",
"hlId":"605f17",
"children":[
"Long-acting reversible contraceptive methods are highly effective and include intrauterine devices (copper and levonorgestrel-releasing) as well as a progestin implant."
]
},
{
"type":"keypoint",
"hlId":"78ef95",
"children":[
"Women considering pregnancy should undergo a comprehensive assessment of risk factors for adverse pregnancy outcomes and begin folic acid supplementation."
]
},
{
"type":"keypoint",
"hlId":"367b62",
"children":[
"Women in the postpartum period should have a complete evaluation, with attention paid to long-term risk for gestational diabetes and hypertensive disorders of pregnancy."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_3",
"title":{
"__html":"Menstrual Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"f58d73",
"children":[
"Menstrual Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_3_1",
"title":{
"__html":"Abnormal Uterine Bleeding"
},
"titleNode":{
"type":"section-title",
"hlId":"cff358",
"children":[
"Abnormal Uterine Bleeding"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_3_1_1",
"title":{
"__html":"Evaluation"
},
"titleNode":{
"type":"section-title",
"hlId":"b74a43",
"children":[
"Evaluation"
]
},
"children":[
{
"type":"p",
"hlId":"71d046",
"children":[
"Abnormal uterine bleeding is defined as excessive bleeding in terms of flow volume, frequency, or duration. Among nonpregnant women of reproductive age, abnormal uterine bleeding is classified according to etiology by using the International Federation of Gynaecology and Obstetrics system with the acronym PALM-COEIN (Polyp, Adenomyosis, Leiomyoma, Malignancy and hyperplasia, Coagulopathy, Ovulation dysfunction, Endometrial, Iatrogenic, and Not yet classified). Abnormal uterine bleeding in this population can be further classified as ovulatory or anovulatory. Ovulatory bleeding is accentuation of the cyclic menstrual bleeding. In anovulatory bleeding, the lack of ovulation and cyclic progesterone cause irregular bleeding, endometrial hyperplasia, and increased risk for endometrial cancer. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t51",
"wrapId":"6",
"children":[
"Table 51"
]
}
]
},
" describes the characteristics and causes of abnormal uterine bleeding."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_gm_t51"
]
},
{
"type":"p",
"hlId":"6588a8",
"children":[
"Evaluation of abnormal uterine bleeding in the premenopausal woman starts with a detailed history, including assessment of menstrual history and past medical and gynecologic history. Physical examination should assess for evidence of acute bleeding. Pelvic examination can determine the source of the bleeding, assess for trauma to the genital track, and look for uterine enlargement or irregularity. Initial laboratory testing includes a pregnancy test and complete blood count. Additional testing should be based on clinical indications and may include coagulation tests, TSH level, iron studies, and hormone levels."
]
},
{
"type":"p",
"hlId":"94960c",
"children":[
"Transvaginal ultrasonography is often performed to assess for structural abnormalities and endometrial thickness. Endometrial thickness greater than 4 mm in postmenopausal women may indicate endometrial hyperplasia or malignancy and necessitates biopsy. Proceeding directly to biopsy without ultrasound is also a reasonable alternative in postmenopausal women with uterine bleeding."
]
},
{
"type":"p",
"hlId":"1c2376",
"children":[
"In premenopausal women, endometrial thickness is not a reliable indicator because thickness varies according to the phase of the menstrual cycle. Regardless of endometrial thickness, endometrial biopsy should be done in premenopausal women aged 45 years or older or those younger than 45 years who are at increased risk for endometrial cancer secondary to a history of unopposed estrogen (polycystic ovary syndrome, obesity); tamoxifen use; Lynch or Cowden syndrome; or reproductive factors, such as early menarche, nulliparity, and late menopause."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_3_1_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"48fe5e",
"children":[
"Management of abnormal uterine bleeding is aimed at the underlying cause. Structural abnormalities, such as endometrial polyps or submucosal fibroids, may be surgically resected. Treatment of underlying endocrine disorders (thyroid disease, polycystic ovary syndrome) may result in improvement."
]
},
{
"type":"p",
"hlId":"fd5ada",
"children":[
"For women with anovulatory cycles, treatment is aimed at providing adequate progestin to maintain endometrial stability. The type of therapy depends on the patient's plans for contraception. For women who wish to preserve fertility, medroxyprogesterone acetate used for the second half of the menstrual cycle will restore cyclic withdrawal bleeding. For women interested in contraception, oral contraceptive pills containing estrogen and progesterone, the LNG-IUD, or depot medroxyprogesterone may be used. NSAIDs may also be used because these drugs reduce synthesis of prostaglandins in the endometrium, leading to vasoconstriction and reduced bleeding. Tranexamic acid, an antithrombolytic agent, stabilizes clots and may be used for treatment of heavy vaginal bleeding and in women who cannot tolerate hormonal treatment."
]
},
{
"type":"p",
"hlId":"52440c",
"children":[
"For women experiencing acute and severe bleeding, such agents as gonadotropin-releasing hormone or intravenous administration of high-dose estrogens may be used. For women who do not respond to medical therapy, operative procedures, such as endometrial ablation, uterine artery embolization, or hysterectomy, may be performed."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_3_2",
"title":{
"__html":"Dysmenorrhea"
},
"titleNode":{
"type":"section-title",
"hlId":"134097",
"children":[
"Dysmenorrhea"
]
},
"children":[
{
"type":"p",
"hlId":"8db093",
"children":[
"Dysmenorrhea is characterized by pain during menstruation; it may also be associated with low back pain, headache, nausea, vomiting, and diarrhea. Dysmenorrhea is classified as primary or secondary. Primary dysmenorrhea involves cramping lower abdominal and pelvic pain that occurs during menstrual cycles without an identifiable cause. Secondary dysmenorrhea may result from pelvic conditions, of which endometriosis is the most common."
]
},
{
"type":"p",
"hlId":"f7fb73",
"children":[
"A detailed history is necessary to assess the timing of pain and relationship to the menstrual cycle. Sexual history is important to assess for infection risk. Primary dysmenorrhea can be treated with NSAIDs or contraception, including estrogen-progesterone and progesterone-only methods. Secondary dysmenorrhea requires treatment of the underlying condition."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f669bd",
"children":[
"Evaluation of all patients with abnormal uterine bleeding includes a detailed history, physical and pelvic examinations, and pregnancy testing and complete blood count; additional testing should be based on clinical indications."
]
},
{
"type":"keypoint",
"hlId":"7b4dbc",
"children":[
"Risk factors for endometrial cancer include age older than 45 years; anovulatory bleeding; tamoxifen use; Lynch or Cowden syndrome; obesity; and reproductive factors, such as early menarche, nulliparity, and late menopause."
]
},
{
"type":"keypoint",
"hlId":"6bdd24",
"children":[
"Primary dysmenorrhea can be treated with NSAIDs or estrogen-progesterone or progesterone-only methods of contraception."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_4",
"title":{
"__html":"Menopause"
},
"titleNode":{
"type":"section-title",
"hlId":"caf900",
"children":[
"Menopause"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_4_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"9ca87e",
"children":[
"Menopause is the permanent cessation of menses. It is diagnosed retrospectively after a woman has not experienced a menstrual period for 12 months. Menopause may be natural; surgical, after bilateral oophorectomy; or medical, as a result of such treatments as chemotherapy. Menopause occurring before age 40 years is considered premature menopause or premature ovarian insufficiency. Perimenopause refers to the years preceding menopause when ovarian function declines and is often associated with anovulatory cycles and hot flashes."
]
},
{
"type":"p",
"hlId":"556898",
"children":[
"Symptoms of menopause include vasomotor symptoms (hot flashes, night sweats). Hot flashes generally start in the perimenopausal period and can last for a few years to lifelong. Women may experience other symptoms, such as depression, anxiety, and irritability, but it is unclear whether these symptoms can be attributed to menopause. Genitourinary syndrome of menopause results from estrogen deficiency and is characterized by vaginal symptoms, such as burning or irritation; sexual symptoms, such as dyspareunia or sexual dysfunction; or urinary symptoms, such as dysuria or recurrent urinary infections. Pelvic examination findings include a pale, dry vaginal lining with reduction in rugae. Increases in LDL cholesterol and bone loss may also occur ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_gm_f04",
"wrapId":"7",
"children":[
"Figure 4"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_gm_f04"
]
},
{
"type":"p",
"hlId":"6edb57",
"children":[
"Routine laboratory testing for the diagnosis of menopause is not recommended. Patients with possible early menopause should have pregnancy excluded and undergo measurement of follicle-stimulating hormone, TSH, and prolactin. Younger patients should undergo evaluation for amenorrhea (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s5_2_2",
"children":[
"MKSAP 19 Endocrinology and Metabolism"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_4_2",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"6a6de3",
"children":[
"It is important to remember that in the perimenopausal period, pregnancy is possible even if menstrual cycles are irregular, and contraception should be discussed if pregnancy is not desired. Although there is no role for hormone therapy in the prevention of chronic health conditions, it remains the most effective treatment for vasomotor symptoms and may improve quality of life. Hormone therapy is safest when initiated within 10 years of menopause."
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_4_2_1",
"title":{
"__html":"Vasomotor Symptoms"
},
"titleNode":{
"type":"section-title",
"hlId":"b53867",
"children":[
"Vasomotor Symptoms"
]
},
"children":[
{
"type":"p",
"hlId":"4b09de",
"children":[
"The approach to initiating menopausal hormone therapy for women younger than 60 years or within 10 years of menopause onset is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t52",
"wrapId":"8",
"children":[
"Table 52"
]
}
]
},
". Estrogen is the most effective therapy for vasomotor symptoms; the lowest dose of estrogen to manage symptoms should be used. Women who have an intact uterus also require progestin either dosed continuously or cyclically to avoid estrogen-related endometrial proliferation. Continuous daily estrogen with progestin does not result in cyclic vaginal bleeding, whereas estrogen with cyclic progestin will result in withdrawal bleeding. Common contraindications to hormone therapy include pregnancy, unexplained vaginal bleeding, liver disease, coronary artery disease, stroke, thromboembolic disease, breast cancer, and endometrial cancer. Adverse events associated with estrogen therapy include cardiovascular disease and VTE. Transdermal estrogen is preferable to oral estrogen because it is associated with less thromboembolic risk."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_gm_t52"
]
},
{
"type":"p",
"hlId":"97b857",
"children":[
"Use of hormone therapy for more than 1 year has also been associated with breast cancer in a dose-dependent manner; longer use results in greater risk. Estrogen with daily progestin results in the highest risk for breast cancer, whereas estrogen-only hormone therapy has the lowest risk. All women considering hormone therapy should receive individualized breast cancer risk assessment and counseling. Use of hormone therapy in menopause should be reassessed every year to determine benefits and risks. Treatment duration is based on continued presence of vasomotor symptoms."
]
},
{
"type":"p",
"hlId":"ec7ae1",
"children":[
"For women who prefer not to use or have contraindications to hormone therapy, nonhormonal drugs can help modulate vasomotor symptoms. Antidepressant agents, including selective serotonin reuptake inhibitors (such as citalopram, escitalopram, and paroxetine) and serotonin-norepinephrine reuptake inhibitors (such as venlafaxine, desvenlafaxine, and duloxetine), gabapentin, pregabalin, and clonidine, are effective. Research is inconclusive regarding supplements, such as soy, black cohosh, and other phytoestrogens, for treating vasomotor symptoms."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_4_2_2",
"title":{
"__html":"Genitourinary Syndrome of Menopause"
},
"titleNode":{
"type":"section-title",
"hlId":"d5e078",
"children":[
"Genitourinary Syndrome of Menopause"
]
},
"children":[
{
"type":"p",
"hlId":"20e1bf",
"children":[
"Management of genitourinary syndrome of menopause (GSM) includes topical nonhormonal and hormonal preparations to relieve symptoms. Nonhormonal approaches include as-needed vaginal lubricants for intercourse and vaginal moisturizers that can alleviate vaginal dryness and irritation when used regularly. The North American Menopause Society recommends nonhormonal vaginal therapies as first-line treatment for GSM."
]
},
{
"type":"p",
"hlId":"a008b6",
"children":[
"Hormonal preparations include estradiol or conjugated estrogen in tablet, cream, or ring forms. Low-dose vaginal estrogen is recommended for the management of vaginal atrophy because it builds the vaginal epithelium and restores the acidic pH and microenvironment. Moreover, improving the lining of the lower urethra reduces dysuria and recurrent urinary tract infection. For women with breast cancer (current or past), low-dose vaginal hormone therapy should be given only with the approval of the treating oncologist. Vaginal dehydroepiandrosterone and the selective estrogen receptor modulator ospemifene are both FDA approved for management of dyspareunia associated with GSM; most experts consider these treatment modalities second-line therapies because of their side effects and limited safety experience."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"afb149",
"hvc":true,
"children":[
"Routine laboratory testing for the diagnosis of menopause is not recommended; patients with possible early menopause should have pregnancy excluded and undergo measurement of follicle-stimulating hormone, thyroid-stimulating hormone, and prolactin."
]
},
{
"type":"keypoint",
"hlId":"37a975",
"children":[
"In the perimenopausal period, pregnancy is possible even if menstrual cycles are irregular, and contraception should be discussed if pregnancy is not desired."
]
},
{
"type":"keypoint",
"hlId":"bbb95c",
"children":[
"Estrogen is the most effective therapy for vasomotor symptoms of menopause."
]
},
{
"type":"keypoint",
"hlId":"7d2590",
"children":[
"Nonhormonal options for vasomotor symptoms of menopause include antidepressant agents, gabapentin, pregabalin, and clonidine."
]
},
{
"type":"keypoint",
"hlId":"ae2420",
"children":[
"Management of genitourinary syndrome of menopause includes topical nonhormonal and hormonal preparations to achieve symptom relief."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_5",
"title":{
"__html":"Pelvic Pain"
},
"titleNode":{
"type":"section-title",
"hlId":"223054",
"children":[
"Pelvic Pain"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s7_5_1",
"title":{
"__html":"Acute Pelvic Pain"
},
"titleNode":{
"type":"section-title",
"hlId":"91b460",
"children":[
"Acute Pelvic Pain"
]
},
"children":[
{
"type":"p",
"hlId":"b66949",
"children":[
"Although the differential diagnosis of acute pelvic pain is broad, clinicians should consider several critical diagnoses, including ectopic pregnancy, pelvic inflammatory disease (PID), ruptured ovarian cyst, ovarian torsion, and appendicitis, when evaluating a woman with acute pelvic pain."
]
},
{
"type":"p",
"hlId":"e65e49",
"children":[
"History should elicit the characteristics of the pain, including location, radiation, severity, timing, duration, and alleviating and aggravating factors. Medical history should note previous abdominal or gynecologic diagnoses or surgeries. A sexual history should be obtained for all patients. The physical examination should focus on vital signs, abdominal examination, and pelvic examination, specifically a bimanual examination to assess for fundal and adnexal tenderness or masses."
]
},
{
"type":"p",
"hlId":"0ead0f",
"children":[
"A pregnancy test should be obtained for all women of reproductive age presenting with acute pelvic pain. Any woman with a positive pregnancy test should have ectopic pregnancy excluded before other diagnoses are considered. Other laboratory testing may include STI testing, complete blood cell count, and type and screen depending on the clinical scenario. Transvaginal ultrasonography can help diagnosis ectopic pregnancy, ovarian cysts, ovarian torsion, and tubo-ovarian abscess as a complication of PID."
]
},
{
"type":"p",
"hlId":"97082a",
"children":[
"The management of acute pelvic pain depends on the diagnosis. Women with ectopic pregnancies should be evaluated immediately by an obstetrician for consideration of surgical management versus medical management with methotrexate. The treatment of PID is covered in ",
{
"type":"cross-reference",
"target":"mk19_a_id_s9_5_2",
"children":[
"MKSAP 19 Infectious Disease"
]
},
". Gynecology should be involved in the management of ovarian cysts, particularly for a ruptured hemorrhagic cyst in a patient with unstable vital signs and ovarian torsion, which is considered a surgical emergency. Appendicitis requires surgical consultation."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_5_2",
"title":{
"__html":"Chronic Pelvic Pain"
},
"titleNode":{
"type":"section-title",
"hlId":"9d3df4",
"children":[
"Chronic Pelvic Pain"
]
},
"children":[
{
"type":"p",
"hlId":"166617",
"children":[
"Chronic pelvic pain (CPP) refers to nonmenstrual pelvic pain of at least 6 months' duration that is severe enough to result in functional disability requiring medical care. Evaluation and diagnosis of CPP are challenging because it is often multifactorial and involves both physiologic and psychological components. Risk factors for CPP include physical, sexual, and/or emotional abuse; PID; history of abdominopelvic surgery; chronic pain syndromes; and psychological conditions, such as anxiety or depression."
]
},
{
"type":"p",
"hlId":"ad8167",
"children":[
"Common causes of CPP can be classified as gynecologic, gastrointestinal, urologic, and musculoskeletal/neurologic and are outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t53",
"wrapId":"9",
"children":[
"Table 53"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_gm_t53"
]
},
{
"type":"p",
"hlId":"b7dcd0",
"children":[
"Evaluation includes a detailed history to determine characteristics of the pain, including association with menstrual cycle, urination, or bowel movement, as well as assessment for risk factors and known causes of CPP. The presence of physical examination includes detailed abdominal and gynecologic examinations. Laboratory testing is of limited value unless specific disorders are suggested by the history and clinical examination (such as urinalysis for urinary tract infection or STI testing). Transvaginal ultrasonography is used to identify anatomic pathology, such as a pelvic mass. In the absence of an abnormality noted on clinical examination or ultrasound, laparoscopy may be helpful for the evaluation of severe symptoms of unclear cause to assess for conditions such as endometriosis."
]
},
{
"type":"p",
"hlId":"6b210f",
"children":[
"Treatment is aimed at the underlying cause and may be challenging if no clear cause is identified. Menstrual suppression with hormonal contraception can help many patients. Pelvic floor physical therapy, cognitive behavioral therapy, and sex therapy are recommended. Serotonin-norepinephrine reuptake inhibitors, gabapentin, and pregabalin may be helpful in patients with neuropathic pain. Trigger point injections should be considered in myofascial chronic pelvic pain. Acupuncture and yoga may be helpful for some patients. NSAIDs may be helpful for patients with moderate CPP. Routine surgical lysis of adhesions is not indicated. Peripheral nerve block or surgical release can also be used for suspected nerve impingement or entrapment."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_5_3",
"title":{
"__html":"Uterine Fibroids"
},
"titleNode":{
"type":"section-title",
"hlId":"6831f9",
"children":[
"Uterine Fibroids"
]
},
"children":[
{
"type":"p",
"hlId":"74e17c",
"children":[
"Uterine fibroids are the most common pelvic tumor in females. Risk factors include early menarche, obesity, diabetes, and family history. Although they are asymptomatic in many patients, mass effect may lead to pelvic pain, and impingement on the bladder or bowel may lead to urinary or bowel symptoms. Masses may also result in compromised fertility secondary to changes in uterine shape. Abnormal uterine bleeding, usually manifest as heavy menstrual flow and dysmenorrhea, are also common, especially with submucosal fibroids."
]
},
{
"type":"p",
"hlId":"5114fd",
"children":[
"Diagnosis is often suggested by the presence of an abnormal uterus on physical examination, but transvaginal ultrasonography is diagnostic. Advanced imaging, such as MRI, is rarely necessary, except for planning of surgical therapy."
]
},
{
"type":"p",
"hlId":"e18512",
"children":[
"Treatment is dictated by symptoms. In patients with pain secondary to mass effect, surgery may be appropriate with the modality determined by patient preference, including desire for preservation of fertility. Hysterectomy, myomectomy, and uterine artery embolization may be appropriate in selected patients. Hysteroscopic myomectomy is first-line therapy for symptomatic submucosal fibroids, including those causing abnormal bleeding. In patients with heavy or painful bleeding, combined oral contraceptives are an effective option. A progestin-based intrauterine device may also be useful in selected patients."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_5_4",
"title":{
"__html":"Endometriosis"
},
"titleNode":{
"type":"section-title",
"hlId":"41b2cc",
"children":[
"Endometriosis"
]
},
"children":[
{
"type":"p",
"hlId":"83b166",
"children":[
"Endometriosis is the presence of endometrial tissue external to the uterus. The most common location is the ovaries, but it may occur anywhere in the pelvis, including the fallopian tubes, posterior cul-de-sac, colon, and round ligaments. Endometriosis may be present in 6% to 10% of reproductive-age females, but the clinical presentation is variable. Chronic pain, dyspareunia, and dysmenorrhea are common and infertility may also be present. The physical examination may show localized areas of tenderness or palpable masses in involved areas, but can be normal. Transvaginal ultrasonography is the first step in the evaluation of possible endometriosis and although a definitive diagnosis requires laparoscopy with biopsy, a presumptive diagnosis is often made on clinical grounds."
]
},
{
"type":"p",
"hlId":"7756df",
"children":[
"Treatment is guided by symptoms and extent of disease. Pain is often responsive to continuous combined oral contraceptives or progestins alone. Gonadotropin-releasing hormone agonists are also effective. Ablative surgery may be necessary for extensive disease, refractory symptoms, or infertility."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"da9c1e",
"children":[
"Women presenting with acute pelvic pain should be evaluated for critical diagnoses, including ectopic pregnancy, pelvic inflammatory disease, ruptured ovarian cyst, ovarian torsion, and appendicitis."
]
},
{
"type":"keypoint",
"hlId":"5aea6c",
"children":[
"A pregnancy test should be obtained in all women of reproductive age presenting with acute pelvic pain."
]
},
{
"type":"keypoint",
"hlId":"28dfcb",
"children":[
"Risk factors for chronic pelvic pain include physical, sexual, and/or emotional abuse; pelvic inflammatory disease; history of abdominopelvic surgery; chronic pain syndromes; and psychological conditions, such as anxiety or depression."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_6",
"title":{
"__html":"Female Sexual Dysfunction"
},
"titleNode":{
"type":"section-title",
"hlId":"f53bdb",
"children":[
"Female Sexual Dysfunction"
]
},
"children":[
{
"type":"p",
"hlId":"f88a1e",
"children":[
"Female sexual dysfunction is characterized by persistent or recurrent distressing sexual concerns or difficulties and is likely underappreciated. According to the DSM-5, female sexual dysfunction is divided into three categories: female sexual interest/arousal disorder, female orgasmic disorder, and genito-pelvic pain/penetration disorder."
]
},
{
"type":"p",
"hlId":"596575",
"children":[
"Female sexual interest/arousal disorder is characterized by a lack of or significant decrease in sexual activity. This may include lack of or significant decrease in interest in sexual activity, sexual/erotic thoughts or fantasies, excitement or pleasure during sexual activity, and/or initiation of sexual activity or responding to a partner initiation. Female orgasmic disorder is characterized by a significant delay in, infrequency of, or absence of orgasm, or significantly decreased intensity of orgasm during sexual activity. Genitopelvic pain/penetration disorder is characterized by persistent or recurrent difficulty having sexual intercourse; experiencing vulvovaginal or pelvic pain during intercourse; fear or anxiety about vulvovaginal or pelvic pain; and/or tensing or tightening of pelvic floor muscles during attempted vaginal penetration. Diagnosis of a sexual disorder requires that the symptoms of each disorder occur more than 75% of the time for at least 6 months and cause clinically significant distress."
]
},
{
"type":"p",
"hlId":"4737bb",
"children":[
"Beyond the three categories of female sexual dysfunction, women may experience sexual dysfunction with and after pregnancy. Perinatal events, such as cesarean or instrument delivery or perineal tears, may cause pelvic pain. Estrogen levels are lower during breastfeeding, which may result in vaginal dryness. Postpartum depression may contribute to decreased sexual desire or frequency. Menopause and GSM may also affect sexual function because vaginal dryness may contribute to pain with vaginal intercourse."
]
},
{
"type":"p",
"hlId":"b9df8e",
"children":[
"When assessing sexual function, it is important to realize that sexual functioning involves multiple components, including emotions, relationships, past experiences, physiologic responses, overall health, and personal beliefs; therefore, a comprehensive approach is needed to evaluate and treat the condition."
]
},
{
"type":"p",
"hlId":"58689e",
"children":[
"Assessment of female sexual dysfunction includes detailed questions regarding the patient's sexual and gender identity; symptom characteristics, including duration, acute or gradual onset, and if associated with a specific partner or a generalized concern; association with pain; precipitating events; and level of distress caused by the symptoms. In addition, assessment should include current life stressors; medical and surgical history; medications; and history of physical, emotional, and/or sexual abuse. Screening for concurrent depression is indicated. The Female Sexual Function Index or the Female Sexual Distress Scale can be used during the assessment. Pelvic examination is aimed at assessing for specific sites of pain or tenderness, vaginal dryness, or atrophy. Laboratory testing is of limited value and is performed only if an underlying cause is suspected."
]
},
{
"type":"p",
"hlId":"3289d4",
"children":[
"Therapy is aimed at the underlying cause of female sexual dysfunction, which is often multifactorial. There are two FDA approved medications for female sexual dysfunction. Flibanserin, a serotonin receptor agonist/antagonist, is approved for premenopausal women with female sexual interest/arousal disorder without depression. Its use is limited secondary to side effects (dizziness, syncope, hypotension, somnolence); incidence of side effects is increased when combined with alcohol or certain medications (antidepressants). Bremelanotide is a subcutaneous injection approved for use in premenopausal women, but it can only be used eight times per month and is limited by side effects (skin darkening, nausea, vomiting). Off-label use of bupropion may improve sexual functioning, although extensive data are lacking. Similarly, low-dose testosterone treatment (off-label) increases sexual function scores, but side effects must be discussed and long-term safety data are lacking. In women for whom vaginal dryness and atrophy contribute to their symptoms, vaginal moisturizers and vaginal estrogen therapy may be helpful. Lubricants can be used as needed for intercourse. Pelvic physical therapy and objects, such as dilators, to increase the diameter of the vagina may be used for patients with vulvovaginal pain. Ospemifene is a selective estrogen receptor modulator approved by the FDA for treatment of dyspareunia associated with vulvovaginal atrophy."
]
},
{
"type":"p",
"hlId":"e75090",
"children":[
"Treatment strategies must also address the psychological and behavioral aspects of female sexual dysfunction. Cognitive behavioral therapy can help minimize negative attitudes and help with anxiety. Couples therapy may be beneficial. Sex therapy includes counseling; cognitive behavioral therapy; and treatment of concomitant mental health conditions, such as depression and anxiety."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7aeb3d",
"children":[
"Female sexual dysfunction requires a through history and physical examination and a comprehensive approach to treatment addressing physical, psychological, and behavioral aspects."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_7",
"title":{
"__html":"Vaginitis"
},
"titleNode":{
"type":"section-title",
"hlId":"cb997f",
"children":[
"Vaginitis"
]
},
"children":[
{
"type":"p",
"hlId":"f8eeac",
"children":[
"Vaginitis describes conditions associated with vulvovaginal symptoms that may include vaginal discharge, burning, itching, or odor. The most common causes of vaginitis are bacterial vaginosis, candidiasis, and trichomoniasis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t54",
"wrapId":"10",
"children":[
"Table 54"
]
}
]
},
")"
]
},
". Other causes of vaginitis include irritant vaginitis, allergic vaginitis, and atrophic vaginitis. Normal physiologic vaginal discharge is odorless and is not associated with any irritation."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_gm_t54"
]
},
{
"type":"p",
"hlId":"de1829",
"children":[
"History should include details about the vaginal discharge (volume, color, odor), relation to menstruation, use of douches or other products, sexual history, dysuria, and dyspareunia. Physical examination includes assessment of the vulva and vagina for erythema, edema, excoriation, and discharge. History and physical examination are insufficient for diagnosis, and laboratory testing is necessary. Diagnostic testing includes assessment of vaginal pH, amine (whiff) test, and microscopic evaluation with saline and potassium hydroxide (KOH) wet mounts. Nucleic acid amplication and antigen testing of vaginal discharge is now available to diagnose the common causes of vaginitis."
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_7_1",
"title":{
"__html":"Bacterial Vaginosis"
},
"titleNode":{
"type":"section-title",
"hlId":"89ddef",
"children":[
"Bacterial Vaginosis"
]
},
"children":[
{
"type":"p",
"hlId":"14e20d",
"children":[
"Bacterial vaginosis is the most common cause of vaginitis. It results from the loss of the normal hydrogen peroxide–producing lactobacilli in the vagina, with an increase in the vaginal pH that contributes to an overgrowth of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Gardnerella vaginalis"
]
},
" and other anaerobes. Anaerobic overgrowth results in the production of amines, causing the characteristically malodorous discharge. Patients with bacterial vaginosis are at increased risk for STIs, including HIV infection, and for preterm delivery."
]
},
{
"type":"p",
"hlId":"2e12c2",
"children":[
"More than half of patients with bacterial vaginosis are asymptomatic. Symptomatic patients report a thin vaginal discharge with a fishy odor. Other characteristic findings include a vaginal pH greater than 4.5; a positive whiff test result in which application of 10% KOH to vaginal secretions results in a fishy odor; and the presence of clue cells, vaginal epithelial cells that on microscopy have ill-defined cell borders due to adherent coccobacilli ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_gm_f05",
"wrapId":"11",
"children":[
"Figure 5"
]
}
]
},
")"
]
},
". Diagnostic criteria are presented in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t54",
"wrapId":"11",
"children":[
"Table 54"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_gm_f05",
"mk19_b_gm_t54"
]
},
{
"type":"p",
"hlId":"16586f",
"children":[
"Asymptomatic bacterial vaginosis does not require treatment. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t54",
"wrapId":"12",
"children":[
"Table 54"
]
}
]
},
" outlines treatment options for symptomatic bacterial vaginosis."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_gm_t54"
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_7_2",
"title":{
"__html":"Vulvovaginal Candidiasis"
},
"titleNode":{
"type":"section-title",
"hlId":"4c986e",
"children":[
"Vulvovaginal Candidiasis"
]
},
"children":[
{
"type":"p",
"hlId":"15b018",
"children":[
"Vulvovaginal candidiasis is the second most common cause of vaginitis; it is usually caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida albicans"
]
},
" and less commonly by non-albicans ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
". Unlike pharyngeal candidiasis, it frequently occurs in immunocompetent women with no risk factors. Factors that may increase the risk for vulvovaginal candidiasis include diabetes mellitus, pregnancy, and use of glucocorticoids or antibiotics. Recurrent vulvovaginal candidiasis is categorized as infections occurring three or more times per year."
]
},
{
"type":"p",
"hlId":"6d7bc2",
"children":[
"Vulvovaginal candidiasis is typically characterized by vaginal itching, irritation, and discharge and may be associated with dysuria. Examination reveals vulvar edema and excoriation, with thick, white, curdy vaginal discharge. Diagnostic testing involves 10% KOH wet mount of the discharge showing yeast, hyphae, or pseudohyphae ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_gm_f06",
"wrapId":"13",
"children":[
"Figure 6"
]
}
]
},
")"
]
},
" or positive nucleic acid amplification test. For recurrent infections, cultures are important because patients may have an infection with a non-albicans ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species requiring different treatment."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_gm_f06"
]
},
{
"type":"p",
"hlId":"1c7ccc",
"children":[
"Asymptomatic patients should not receive treatment. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t54",
"wrapId":"14",
"children":[
"Table 54"
]
}
]
},
" for treatment options for symptomatic uncomplicated and complicated vulvovaginal candidiasis. Recurrent symptoms after treatment warrant an evaluation for underlying predisposing factors."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_gm_t54"
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_7_3",
"title":{
"__html":"Trichomoniasis"
},
"titleNode":{
"type":"section-title",
"hlId":"44f3ef",
"children":[
"Trichomoniasis"
]
},
"children":[
{
"type":"p",
"hlId":"a26c5d",
"children":[
"Trichomoniasis is a vaginal infection caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trichomonas vaginalis"
]
},
", a flagellated protozoan, and is a sexually transmitted infection. It is associated with increased risk for preterm labor in pregnancy as well as increased risk for HIV transmission."
]
},
{
"type":"p",
"hlId":"a3d92c",
"children":[
"Women may be asymptomatic or present with copious vaginal discharge that is malodorous; pale yellow, green, or gray; frothy; and associated with vulval itching and burning. Vaginal pH is often elevated, but this is not helpful diagnostically. Although microscopy with examination of a wet mount of the vaginal fluid showing motile trichomonads can be diagnostic, the CDC recommends nucleic acid amplification testing. When ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trichomonas"
]
},
" is identified, testing for other STIs should be considered. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t54",
"wrapId":"15",
"children":[
"Table 54"
]
}
]
},
" for treatment of trichomoniasis. Women should be retested within 3 months of treatment. Treatment of sexual partners is recommended to prevent reinfection."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_b_gm_t54"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7eb192",
"hvc":true,
"children":[
"Clinical findings do not sufficiently distinguish between the common causes of vaginitis, and laboratory testing is necessary to establish a diagnosis in bacterial vaginitis or trichomoniasis."
]
},
{
"type":"keypoint",
"hlId":"657788",
"children":[
"Characteristic findings of bacterial vaginosis includes a thin vaginal discharge, vaginal pH greater than 4.5, a positive whiff test result in which application of 10% potassium hydroxide to vaginal secretions results in a fishy odor, and the presence of clue cells."
]
},
{
"type":"keypoint",
"hlId":"a821e2",
"children":[
"Diagnostic testing for vulvovaginal candidiasis involves 10% potassium hydroxide wet mount showing yeast, hyphae, or pseudohyphae."
]
},
{
"type":"keypoint",
"hlId":"7103c3",
"children":[
"Nucleic acid amplification testing (NAAT) and antigen testing are routinely available to diagnose bacterial vaginosis and vulvovaginal candidiasis; NAAT is the preferred diagnostic test for trichomoniasis."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_8",
"title":{
"__html":"Vulvar Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"162c53",
"children":[
"Vulvar Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"a2cac3",
"children":[
"Vulvar symptoms are often related to diseases and physiologic processes that affect the vagina, including vaginitis and GSM. See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_7",
"children":[
"Vaginitis"
]
},
" and ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_4",
"children":[
"Menopause"
]
},
" for more information. Vulvar cancer, vulvar lichen planus, and vulvar lichen sclerosis may be limited to the vulvar surfaces and are discussed in this section. There is substantial overlap in the clinical presentation of these disorders and biopsy is usually necessary."
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_8_1",
"title":{
"__html":"Vulvar Cancer and Squamous Intraepithelial Lesions"
},
"titleNode":{
"type":"section-title",
"hlId":"4e9db5",
"children":[
"Vulvar Cancer and Squamous Intraepithelial Lesions"
]
},
"children":[
{
"type":"p",
"hlId":"521150",
"children":[
"Vulvar cancer most frequently develops in patients older than age 50 and is usually squamous cell carcinoma linked to chronic inflammation or human papilloma virus infection. It presents as a mass, nodule, or plaque on the vulva that is often asymptomatic but may be friable and bleed. Evaluation of a suspicious lesion includes colposcopy and biopsy."
]
},
{
"type":"p",
"hlId":"6ebcdd",
"children":[
"Vulvar squamous intraepithelial lesions are raised white or macular lesions on the vulva that are frequently multifocal. Although many do not have malignant potential, high-grade lesions may progress to squamous cell carcinoma and colposcopy and biopsy should be performed."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_8_2",
"title":{
"__html":"Lichen Planus"
},
"titleNode":{
"type":"section-title",
"hlId":"ac4120",
"children":[
"Lichen Planus"
]
},
"children":[
{
"type":"p",
"hlId":"0d806b",
"children":[
"Lichen planus is an inflammatory skin disease that frequently involves the mucus membranes, including the vulva. Symptoms include pain, pruritus, and burning. Examination findings are variable and may include flat-topped purple papules or erosions, both of which may demonstrate overlying fine white lacy streaks. In addition to vulvar and vaginal involvement, lesions may be seen on the oral mucosa, flexor surfaces, and the trunk. Biopsy is usually necessary to confirm the diagnosis; most patients respond to topical corticosteroids."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_8_3",
"title":{
"__html":"Lichen Sclerosis"
},
"titleNode":{
"type":"section-title",
"hlId":"07cfb7",
"children":[
"Lichen Sclerosis"
]
},
"children":[
{
"type":"p",
"hlId":"ceb5e5",
"children":[
"Vulvar lichen sclerosis presents as vulvar pruritus, which can be debilitating and have a significant impact on quality of life. Examination shows white vulvar papules or plaques; excoriations secondary to scratching may also be seen. Unlike lichen planus, it is limited to the vulva and typically does not involve the vagina. Biopsy is usually performed to confirm the diagnosis and to assess the possibility of malignancy, especially because lichen sclerosis increases the risk of squamous cell carcinoma. Treatment with high-potency topical corticosteroids is usually effective."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s7_9",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"American College of Obstetricians and Gynecologists committee opinion no. 736. Optimizing postpartum care. Obstet Gynecol. 2018;131:e140-50. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29683911",
"target":"_blank"
},
"children":[
"PMID: 29683911"
]
},
" doi:10.1097/AOG.0000000000002633"
]
},
{
"type":"reference",
"children":[
"American College of Obstetricians and Gynecologists committee opinion no. 762 summary. Prepregnancy counseling. Obstet Gynecol. 2019;133:228-30. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30575672",
"target":"_blank"
},
"children":[
"PMID: 30575672"
]
},
" doi:10.1097/AOG.0000000000003014"
]
},
{
"type":"reference",
"children":[
"American College of Obstetricians and Gynecologists practice bulletin summary no. 213. Female sexual dysfunction. Obstet Gynecol. 2019;134:203-5. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31241595",
"target":"_blank"
},
"children":[
"PMID: 31241595"
]
},
" doi:10.1097/AOG.0000000000003325"
]
},
{
"type":"reference",
"children":[
"American Psychiatric Association. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Diagnostic and Statistical Manual of Mental Disorders."
]
},
" 5th ed. American Psychiatric Association; 2013."
]
},
{
"type":"reference",
"children":[
"Curtis KM, Peipert JF. Long-acting reversible contraception. N Engl J Med. 2017;376:461-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28146650",
"target":"_blank"
},
"children":[
"PMID: 28146650"
]
},
" doi:10.1056/NEJMcp1608736"
]
},
{
"type":"reference",
"children":[
"Holbrook AI, Moy L, Akin EA, et al; Expert Panel on Breast Imaging: ACR appropriateness criteria® breast pain. J Am Coll Radiol. 2018;15:S276-82. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30392596",
"target":"_blank"
},
"children":[
"PMID: 30392596"
]
},
" doi:10.1016/j.jacr.2018.09.014"
]
},
{
"type":"reference",
"children":[
"Moy L, Heller SL, Bailey L, et al; Expert Panel on Breast Imaging:. ACR appropriateness criteria® palpable Breast Masses. J Am Coll Radiol. 2017;14:S203-24. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28473077",
"target":"_blank"
},
"children":[
"PMID: 28473077"
]
},
" doi:10.1016/j.jacr.2017.02.033"
]
},
{
"type":"reference",
"children":[
"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24:728-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28650869",
"target":"_blank"
},
"children":[
"PMID: 28650869"
]
},
" doi:10.1097/GME.0000000000000921"
]
},
{
"type":"reference",
"children":[
"Paladine HL, Blenning CE, Strangas Y. Postpartum care: an approach to the fourth trimester. Am Fam Physician. 2019;100:485-91. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31613576",
"target":"_blank"
},
"children":[
"PMID: 31613576"
]
}
]
},
{
"type":"reference",
"children":[
"Paladine HL, Desai UA. Vaginitis: diagnosis and treatment. Am Fam Physician. 2018;97:321-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29671516",
"target":"_blank"
},
"children":[
"PMID: 29671516"
]
}
]
},
{
"type":"reference",
"children":[
"Salzman B, Collins E, Hersh L. Common breast problems. Am Fam Physician. 2019;99:505-14. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30990294",
"target":"_blank"
},
"children":[
"PMID: 30990294"
]
}
]
},
{
"type":"reference",
"children":[
"Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975-4011. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26444994",
"target":"_blank"
},
"children":[
"PMID: 26444994"
]
},
" doi:10.1210/jc.2015-2236"
]
},
{
"type":"reference",
"children":[
"Woodhams EJ, Gilliam M. Contraception. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201902050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC18-ITC32. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30716758",
"target":"_blank"
},
"children":[
"PMID: 30716758"
]
}
]
},
{
"type":"reference",
"children":[
"Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1-187. [ PMID: 34292926] doi:10.15585/mmwr.rr7004a1"
]
},
{
"type":"reference",
"children":[
"Wouk N, Helton M. Abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2019;99:435-443. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30932448",
"target":"_blank"
},
"children":[
"PMID: 30932448"
]
}
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_gm_t46":{
"id":"mk19_b_gm_t46",
"number":46,
"bookId":"gm2",
"title":{
"__html":"Breast Imaging Reporting and Data System (BI-RADS) Assessment Categories"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"fea3f7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 46. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t46"
}
]
},
"Breast Imaging Reporting and Data System (BI-RADS) Assessment Categories"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5796a8",
"class":"cell txt l",
"children":[
"Category 0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef1730",
"class":"cell txt l",
"children":[
"Mammography: Incomplete—Need additional imaging evaluation and/or prior mammograms for comparison"
]
},
" ",
{
"type":"p",
"hlId":"58e9f2",
"class":"cell txt l",
"children":[
"Ultrasound and MRI: Incomplete—Need additional imaging evaluation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f48c6",
"class":"cell txt l",
"children":[
"Category 1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c137fe",
"class":"cell txt l",
"children":[
"Category 2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0bfd5",
"class":"cell txt l",
"children":[
"Benign"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eac1c5",
"class":"cell txt l",
"children":[
"Category 3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85fbca",
"class":"cell txt l",
"children":[
"Probably benign"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab9a7e",
"class":"cell txt l",
"children":[
"Category 4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6759d",
"class":"cell txt l",
"children":[
"Suspicious"
]
},
" ",
{
"type":"p",
"hlId":"6d9e4e",
"class":"cell txt l",
"children":[
"Mammography and ultrasound:"
]
},
" ",
{
"type":"p",
"hlId":"3c979f",
"class":"cell txt li",
"children":[
"Category 4A: Low suspicion for malignancy"
]
},
" ",
{
"type":"p",
"hlId":"1ab4f6",
"class":"cell txt li",
"children":[
"Category 4B: Moderate suspicion for malignancy"
]
},
" ",
{
"type":"p",
"hlId":"eb76ed",
"class":"cell txt li",
"children":[
"Category 4C: High suspicion for malignancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aabd0e",
"class":"cell txt l",
"children":[
"Category 5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c23e0",
"class":"cell txt l",
"children":[
"Highly suggestive of malignancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb7ae1",
"class":"cell txt l",
"children":[
"Category 6"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56d5c5",
"class":"cell txt l",
"children":[
"Known biopsy-proven malignancy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Reproduced with permission of the American College of Radiology (ACR) from D’Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"®"
]
},
" Atlas, Breast Imaging Reporting and Data System. Reston, VA, American College of Radiology; 2013. No other representation of this material is authorized without expressed, written permission from the ACR. Refer to the ACR website at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads",
"target":"_blank"
},
"children":[
"www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads"
]
},
" for the most current and complete version of the BI-RADS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"®"
]
},
" Atlas."
]
]
},
"mk19_b_gm_t47":{
"id":"mk19_b_gm_t47",
"number":47,
"bookId":"gm2",
"title":{
"__html":"Comparison of Contraceptive Options"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"adba18",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 47. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t47"
}
]
},
"Comparison of Contraceptive Options"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"57ea73",
"class":"col hd l",
"children":[
"Women Experiencing Unintended Pregnancy Within the First Year of Use (%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bfc44c",
"class":"col hd l",
"children":[
"Typical Use",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0db3cc",
"class":"col hd l",
"children":[
"Perfect Use",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7b2ce",
"class":"col hd l",
"children":[
"Advantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd l",
"children":[
"Disadvantages"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"143416",
"class":"col hd l",
"children":[
"Hormonal Contraception"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6d6f4",
"class":"col hd l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Combined hormonal (estrogen-progesterone) contraception"
]
},
" "
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da1bbd",
"class":"cell txt l",
"children":[
"Oral contraceptive pill"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e85b79",
"class":"cell txt l",
"children":[
"0.3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a53789",
"class":"cell txt l",
"children":[
"Easy to use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b07ca",
"class":"cell txt l",
"children":[
"Daily oral pill"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"597cbf",
"class":"cell txt l",
"children":[
"Transdermal patch"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e85b79",
"class":"cell txt l",
"children":[
"0.3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac5d8e",
"class":"cell txt l",
"children":[
"Single patch changed weekly"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b222ce",
"class":"cell txt l",
"children":[
"Higher levels of estrogen, increased VTE risk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3283df",
"class":"cell txt l",
"children":[
"Vaginal ring"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e85b79",
"class":"cell txt l",
"children":[
"0.3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6ac72",
"class":"cell txt l",
"children":[
"Ring changed every 3 weeks"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"386369",
"class":"col hd l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Progesterone-only contraception"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da1bbd",
"class":"cell txt l",
"children":[
"Oral contraceptive pill"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8dbe7e",
"class":"cell txt l",
"children":[
"Safe when estrogen is contraindicated"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24252d",
"class":"cell txt l",
"children":[
"Irregular bleeding, breakthrough bleeding"
]
},
" ",
{
"type":"p",
"hlId":"601c7e",
"class":"cell txt l",
"children":[
"Must maintain a daily schedule"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f056ae",
"class":"cell txt l",
"children":[
"Depot medroxyprogesterone acetate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d522d",
"class":"cell txt l",
"children":[
"0.2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71a4c8",
"class":"cell txt l",
"children":[
"Administered every 3 months"
]
},
" ",
{
"type":"p",
"hlId":"296701",
"class":"cell txt l",
"children":[
"Decreases menstrual frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"629f36",
"class":"cell txt l",
"children":[
"Irregular bleeding"
]
},
" ",
{
"type":"p",
"hlId":"2d7fcf",
"class":"cell txt l",
"children":[
"Delayed return to fertility (up to 10 mo)"
]
},
" ",
{
"type":"p",
"hlId":"079c58",
"class":"cell txt l",
"children":[
"Weight gain, decreased bone mineral density"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a932c",
"class":"col hd l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Long-acting reversible contraception"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18fab9",
"class":"cell txt l",
"children":[
"Intrauterine devices"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4090f",
"class":"cell txt li",
"children":[
"Copper"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57eeec",
"class":"cell txt l",
"children":[
"0.8"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e95e1c",
"class":"cell txt l",
"children":[
"0.6"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0f5bd",
"class":"cell txt l",
"children":[
"Nonhormonal"
]
},
" ",
{
"type":"p",
"hlId":"3838ef",
"class":"cell txt l",
"children":[
"Effective up to 10 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd9340",
"class":"cell txt l",
"children":[
"Bleeding and pain with insertion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e3718",
"class":"cell txt li",
"children":[
"Levonorgestrel"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb5ae1",
"class":"cell txt l",
"children":[
"0.1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb5ae1",
"class":"cell txt l",
"children":[
"0.1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2672af",
"class":"cell txt l",
"children":[
"Effective 3-5 y"
]
},
" ",
{
"type":"p",
"hlId":"235322",
"class":"cell txt l",
"children":[
"Decreased menstrual bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4bfb92",
"class":"cell txt l",
"children":[
"Requires office visit for insertion and removal"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"147b40",
"class":"cell txt l",
"children":[
"Progesterone subdermal implant"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b14399",
"class":"cell txt l",
"children":[
"0.05"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b14399",
"class":"cell txt l",
"children":[
"0.05"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9cc8a",
"class":"cell txt l",
"children":[
"Effective up to 3 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"629f36",
"class":"cell txt l",
"children":[
"Irregular bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ec6bb",
"class":"col hd l",
"children":[
"Topical Sperm Inhibitors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"861ebc",
"class":"cell txt l",
"children":[
"Nonoxynol-9 (spermicide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f3671",
"class":"cell txt l",
"children":[
"20-30"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f3671",
"class":"cell txt l",
"children":[
"20-30"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e246ea",
"class":"cell txt l",
"children":[
"On-demand use"
]
},
" ",
{
"type":"p",
"hlId":"eecb13",
"class":"cell txt l",
"children":[
"No systemic effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e24de",
"class":"cell txt l",
"children":[
"Vaginal irritation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d2357",
"class":"cell txt l",
"children":[
"Lactic acid, citric acid, and potassium bitartrate vaginal gel (sperm mobility inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aab323",
"class":"cell txt l",
"children":[
"14"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e246ea",
"class":"cell txt l",
"children":[
"On-demand use"
]
},
" ",
{
"type":"p",
"hlId":"d0f5bd",
"class":"cell txt l",
"children":[
"Nonhormonal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e24de",
"class":"cell txt l",
"children":[
"Vaginal irritation"
]
},
" ",
{
"type":"p",
"hlId":"779248",
"class":"cell txt l",
"children":[
"Urinary tract infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"844983",
"class":"col hd l",
"children":[
"Barrier Methods"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58de2a",
"class":"cell txt l",
"children":[
"Cervical cap"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"419254",
"class":"cell txt l",
"children":[
"16-32"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c1a82",
"class":"cell txt l",
"children":[
"9-26"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7746ca",
"class":"cell txt l",
"children":[
"User dependent"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"865b0c",
"class":"cell txt l",
"children":[
"Vaginal sponge"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ae0f3",
"class":"cell txt l",
"children":[
"14-27"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d83805",
"class":"cell txt l",
"children":[
"9-20"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70dae1",
"class":"cell txt l",
"children":[
"Diaphragm"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70efdf",
"class":"cell txt l",
"children":[
"17"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c74d97",
"class":"cell txt l",
"children":[
"16"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e23a35",
"class":"cell txt l",
"children":[
"Requires spermicide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5a8e8",
"class":"cell txt l",
"children":[
"Male condom"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c51ce4",
"class":"cell txt l",
"children":[
"13"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29424f",
"class":"cell txt l",
"children":[
"Protection from STIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"119e8d",
"class":"cell txt l",
"children":[
"Female condom"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c59dc",
"class":"cell txt l",
"children":[
"21"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29424f",
"class":"cell txt l",
"children":[
"Protection from STIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37ce74",
"class":"cell txt l",
"children":[
"–"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"c9cc5e",
"class":"col hd l",
"children":[
"Permanent Methods"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a227f",
"class":"col hd l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Sterilization"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_6-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e5a140",
"class":"cell txt l",
"children":[
"Female (tubal occlusion)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d310cb",
"class":"cell txt l",
"children":[
"0.5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d310cb",
"class":"cell txt l",
"children":[
"0.5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f1a60",
"class":"cell txt l",
"children":[
"Salpingectomy reduces ovarian cancer risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16a6b8",
"class":"cell txt l",
"children":[
"Increased risk for ectopic pregnancy"
]
},
" ",
{
"type":"p",
"hlId":"7678c9",
"class":"cell txt l",
"children":[
"Procedural complication (rare)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_6-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"183359",
"class":"cell txt l",
"children":[
"Male (vasectomy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9ffc7a",
"class":"cell txt l",
"children":[
"0.15"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb5ae1",
"class":"cell txt l",
"children":[
"0.1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac149",
"class":"cell txt l",
"children":[
"Lower cost, fewer complications, and more effective than female sterilization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7678c9",
"class":"cell txt l",
"children":[
"Procedural complication (rare)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"STI = sexually transmitted infection; VTE = venous thromboembolism."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Perfect use implies correct and consistent use exactly as directed/intended. Typical use reflects rates in actual practice with patients."
]
]
},
"mk19_b_gm_t48":{
"id":"mk19_b_gm_t48",
"number":48,
"bookId":"gm2",
"title":{
"__html":"Preconception Risk Assessment"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"801fbd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 48. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t48"
}
]
},
"Preconception Risk Assessment"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eebef",
"class":"col hd l",
"children":[
"Risk Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fa7b5",
"class":"col hd l",
"children":[
"Specific Items to Assess"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a61eb",
"class":"cell txt l",
"children":[
"Family planning and pregnancy spacing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d76ac",
"class":"cell txt l",
"children":[
"Desire for pregnancy; number and timing of desired pregnancies; age-related changes in fertility, sexuality, contraception"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab2e8f",
"class":"cell txt l",
"children":[
"Environmental hazards and toxins"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"491f4d",
"class":"cell txt l",
"children":[
"Exposure to radiation, lead, and mercury"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c5d54",
"class":"cell txt l",
"children":[
"Nutrition and folic acid consumption"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f5672",
"class":"cell txt l",
"children":[
"Healthy diet; folic acid supplementation; recommended daily intake of iron; restricting consumption of fish with high mercury levels (e.g., shark, swordfish, king mackerel, and tilefish)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dec501",
"class":"cell txt l",
"children":[
"Genetics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03257b",
"class":"cell txt l",
"children":[
"Family history of genetic disorders"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3ab4b",
"class":"cell txt l",
"children":[
"Substance use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e479ec",
"class":"cell txt l",
"children":[
"Use of tobacco, alcohol, marijuana, and illicit drugs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9772fd",
"class":"cell txt l",
"children":[
"Medical conditions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bdd7f2",
"class":"cell txt l",
"children":[
"Diabetes mellitus, hypertension, thyroid disease, HIV infection, bariatric surgery, mood disorders, thrombophilia, asthma, seizure disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8632e2",
"class":"cell txt l",
"children":[
"Obstetric history"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7581b4",
"class":"cell txt l",
"children":[
"Gestational hypertension, preeclampsia, gestational diabetes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba25cf",
"class":"cell txt l",
"children":[
"Medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fed158",
"class":"cell txt l",
"children":[
"Over-the-counter and prescription medications, potential teratogens"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f00045",
"class":"cell txt l",
"children":[
"Infectious diseases and vaccinations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"624772",
"class":"cell txt l",
"children":[
"Vaccinations up to date; immunity to varicella and rubella; risk for HIV and hepatitis B infection; need for STI screening; potential exposure to Zika virus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92daaa",
"class":"cell txt l",
"children":[
"Psychosocial concerns"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f7976",
"class":"cell txt l",
"children":[
"Depression, interpersonal/family relationships, exposure to violence, risk for abuse (physical, sexual, emotional)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"STI = sexually transmitted infection."
],
[
"Information from American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 762 Summary: Prepregnancy counseling. Obstet Gynecol. 2019;133:228-230. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30575672",
"target":"_blank"
},
"children":[
"PMID: 30575672"
]
},
" doi:10.1097/AOG.0000000000003014"
]
]
},
"mk19_b_gm_t49":{
"id":"mk19_b_gm_t49",
"number":49,
"bookId":"gm2",
"title":{
"__html":"Commonly Used Medications With Potential for Teratogenic Effects"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b8ca21",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 49. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t49"
}
]
},
"Commonly Used Medications With Potential for Teratogenic Effects"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d142f7",
"class":"col hd l",
"children":[
"Class/Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff7c0f",
"class":"col hd l",
"children":[
"Examples"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"445236",
"class":"cell txt l",
"children":[
"Antibiotics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b72555",
"class":"cell txt l",
"children":[
"Tetracyclines, sulfonamides, trimethoprim, fluoroquinolones"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6b422",
"class":"cell txt l",
"children":[
"Anticoagulants"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"458c56",
"class":"cell txt l",
"children":[
"Warfarin, direct oral anticoagulants"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55c75c",
"class":"cell txt l",
"children":[
"Antidepressants/mood stabilizers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0a569",
"class":"cell txt l",
"children":[
"Lithium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bb2bf",
"class":"cell txt l",
"children":[
"Antihypertensive agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d681e1",
"class":"cell txt l",
"children":[
"ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"329af3",
"class":"cell txt l",
"children":[
"Antiepileptic drugs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6cd48",
"class":"cell txt l",
"children":[
"Valproic acid, phenytoin, carbamazepine, topiramate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5237eb",
"class":"cell txt l",
"children":[
"Antithyroid medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0af26",
"class":"cell txt l",
"children":[
"Propylthiouracil, carbimazole, methimazole"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a0950",
"class":"cell txt l",
"children":[
"Hormones"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5eda7",
"class":"cell txt l",
"children":[
"Androgens, testosterone derivatives"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f172a",
"class":"cell txt l",
"children":[
"Immunosuppressant/chemotherapeutic agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29cd61",
"class":"cell txt l",
"children":[
"Folate antagonists, cyclophosphamide, methotrexate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52ef96",
"class":"cell txt l",
"children":[
"Others"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0589d2",
"class":"cell txt l",
"children":[
"Vitamin A derivatives, statins, NSAIDs, isotretinoin"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_gm_t50":{
"id":"mk19_b_gm_t50",
"number":50,
"bookId":"gm2",
"title":{
"__html":"The Comprehensive Postpartum Visit"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c5f208",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 50. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t50"
}
]
},
"The Comprehensive Postpartum Visit"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2cb05e",
"class":"col hd l",
"children":[
"Component"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94e46c",
"class":"col hd l",
"children":[
"Clinical Steps"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"070468",
"class":"cell txt l",
"children":[
"Physical recovery"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de268b",
"class":"cell txt l",
"children":[
"Assess for perineal or cesarean incision pain and evidence of incision infection"
]
},
" ",
{
"type":"p",
"hlId":"cf6f11",
"class":"cell txt l",
"children":[
"Assess for urinary or fecal incontinence and constipation/hemorrhoids"
]
},
" ",
{
"type":"p",
"hlId":"4515f7",
"class":"cell txt l",
"children":[
"Provide guidance for return to normal physical activity and healthy weight"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4d0c5",
"class":"cell txt l",
"children":[
"Sexual health"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"17d5e8",
"class":"cell txt l",
"children":[
"Provide guidance on resumption of sexual activity, treatment of dyspareunia, and changes to sexuality"
]
},
" ",
{
"type":"p",
"hlId":"ac5887",
"class":"cell txt l",
"children":[
"Assess future reproductive plans, need for contraception, and importance of birth spacing"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a220de",
"class":"cell txt l",
"children":[
"Psychological health"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91382c",
"class":"cell txt l",
"children":[
"Screen for postpartum depression; ensure appropriate follow-up for women with preexisting mental health disorders"
]
},
" ",
{
"type":"p",
"hlId":"d47ffa",
"class":"cell txt l",
"children":[
"Screen for tobacco and substance use; provide referrals if indicated"
]
},
" ",
{
"type":"p",
"hlId":"1ccfd5",
"class":"cell txt l",
"children":[
"Assess for social support and intimate partner violence"
]
},
" ",
{
"type":"p",
"hlId":"d111e4",
"class":"cell txt l",
"children":[
"Assess sleep and fatigue; offer guidance on management of sleep disruption"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a3a6c",
"class":"cell txt l",
"children":[
"Infant care"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a68cd",
"class":"cell txt l",
"children":[
"Provide guidance on child sleep practices"
]
},
" ",
{
"type":"p",
"hlId":"104447",
"class":"cell txt l",
"children":[
"Assess for breastfeeding issues, need for lactation support, and access to breast milk pumping supplies"
]
},
" ",
{
"type":"p",
"hlId":"7eccac",
"class":"cell txt l",
"children":[
"Plan for childcare for return to work or school if indicated"
]
},
" ",
{
"type":"p",
"hlId":"38ac1c",
"class":"cell txt l",
"children":[
"Assess material needs, including housing, food, utilities, and diapers; refer to resources if needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef5c8f",
"class":"cell txt l",
"children":[
"Chronic disease management"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b4cc54",
"class":"cell txt l",
"children":[
"Discuss future risk of preeclampsia and gestational diabetes and risk-mitigation strategies"
]
},
" ",
{
"type":"p",
"hlId":"cfb05c",
"class":"cell txt l",
"children":[
"Screen for gestational diabetes"
]
},
" ",
{
"type":"p",
"hlId":"8afa30",
"class":"cell txt l",
"children":[
"Review medications for safety during lactation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3310b3",
"class":"cell txt l",
"children":[
"Health maintenance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67ac69",
"class":"cell txt l",
"children":[
"Provide immunizations as needed"
]
},
" ",
{
"type":"p",
"hlId":"e7bfab",
"class":"cell txt l",
"children":[
"Screen for cervical cancer as indicated by guidelines"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Recommendations from American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 736: Optimizing postpartum care. Obstet Gynecol. 2018;131:e140-e150. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29683911",
"target":"_blank"
},
"children":[
"PMID: 29683911"
]
},
" doi:10.1097/AOG.0000000000002633 ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" Paladine HL, Blenning CE, Strangas Y. Postpartum care: an approach to the fourth trimester. Am Fam Physician. 2019;100:485-491. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31613576",
"target":"_blank"
},
"children":[
"PMID: 31613576"
]
}
]
]
},
"mk19_b_gm_t51":{
"id":"mk19_b_gm_t51",
"number":51,
"bookId":"gm2",
"title":{
"__html":"Classification of Abnormal Uterine Bleeding of Nonpregnant Women of Reproductive Age"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6bec53",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 51. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t51"
}
]
},
"Classification of Abnormal Uterine Bleeding of Nonpregnant Women of Reproductive Age"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1fa27",
"class":"col hd l",
"children":[
"Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5a7ad",
"class":"col hd l",
"children":[
"Description"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b4b44",
"class":"col hd l",
"children":[
"Associated Causes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4eaf18",
"class":"cell txt l",
"children":[
"Ovulatory bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d47ea",
"class":"cell txt l",
"children":[
"Occurs at regular intervals"
]
},
" ",
{
"type":"p",
"hlId":"db56bd",
"class":"cell txt l",
"children":[
"Menstrual flow is excessive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bf2f8",
"class":"cell txt l",
"children":[
"Thyroid disease, bleeding disorders, structural abnormalities (e.g., uterine fibroids, polyps, adenomyosis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89f930",
"class":"cell txt l",
"children":[
"Anovulatory bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4f0b6",
"class":"cell txt l",
"children":[
"Irregular flow and cycle duration"
]
},
" ",
{
"type":"p",
"hlId":"9c2445",
"class":"cell txt l",
"children":[
"Frequently occurs in the first few years after menarche and during perimenopause"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"575b71",
"class":"cell txt l",
"children":[
"Polycystic ovary syndrome, thyroid diseases, hyperprolactinemia, chronic diseases (e.g., chronic liver or kidney disease)"
]
},
" ",
{
"type":"p",
"hlId":"b51498",
"class":"cell txt l",
"children":[
"Medications (e.g., antipsychotic agents, chemotherapy, tamoxifen)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_gm_t52":{
"id":"mk19_b_gm_t52",
"number":52,
"bookId":"gm2",
"title":{
"__html":"Initiating Systemic Hormone Therapy for Vasomotor Symptoms in Women Younger Than 60 Years or Within 10 Years of Menopause Onset<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f1fb8b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 52. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t52"
}
]
},
"Initiating Systemic Hormone Therapy for Vasomotor Symptoms in Women Younger Than 60 Years or Within 10 Years of Menopause Onset",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ef1da",
"class":"cell txt l",
"children":[
"Step 1: Confirm that hot flashes/night sweats are moderate to severe in intensity and are refractory to lifestyle modifications."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9625da",
"class":"cell txt l",
"children":[
"Step 2: Assess for contraindications to systemic hormone therapy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c2678",
"class":"cell txt l",
"children":[
"Step 3: Assess the patient's baseline risk for CVD, VTE, and breast cancer. For women at increased risk, consider nonhormonal treatments.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b0dcf",
"class":"cell txt l",
"children":[
"Step 4: Use the lowest dose of estrogen that relieves menopausal symptoms."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86b6c1",
"class":"cell txt l",
"children":[
"Step 5: Add systemic progesterone therapy to estrogen therapy in women who have an intact uterus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d93396",
"class":"cell txt l",
"children":[
"Step 6: Assess symptoms and side effects after initiating therapy and adjust the dose of estrogen if symptoms are persistent."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b9573",
"class":"cell txt l",
"children":[
"Step 7: Reassess symptoms and risk factors for CVD, VTE, and breast cancer annually."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd48c7",
"class":"cell txt l",
"children":[
"Step 8: Discontinue systemic hormone therapy if the risks of treatment outweigh the benefits."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CVD = cardiovascular disease; VTE = venous thromboembolism"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"According to the 2017 hormone therapy position statement of the North American Menopause Society, the safety profile of hormone therapy in women who initiate therapy more than 10 years after menopause onset or at age 60 years or older is not as favorable as for younger women, owing to greater absolute risks for CVD, VTE, and breast cancer."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Endocrine Society guidelines recommend that women at high risk for CVD, VTE, or breast cancer consider nonhormonal therapies. For women at moderate risk for CVD or VTE who still desire hormone therapy, transdermal estrogen, which has less risk versus oral preparations of estrogen, should be considered."
]
]
},
"mk19_b_gm_t53":{
"id":"mk19_b_gm_t53",
"number":53,
"bookId":"gm2",
"title":{
"__html":"Common Causes of Chronic Pelvic Pain"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b728fb",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 53. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t53"
}
]
},
"Common Causes of Chronic Pelvic Pain"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e30934",
"class":"col hd l",
"children":[
"Gynecologic Causes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41b2cc",
"class":"cell txt l",
"children":[
"Endometriosis"
]
},
" ",
{
"type":"p",
"hlId":"63e3e9",
"class":"cell txt l",
"children":[
"Pelvic adhesions"
]
},
" ",
{
"type":"p",
"hlId":"530f7e",
"class":"cell txt l",
"children":[
"Chronic pelvic inflammatory disease"
]
},
" ",
{
"type":"p",
"hlId":"9711f8",
"class":"cell txt l",
"children":[
"Adenomyosis"
]
},
" ",
{
"type":"p",
"hlId":"7d9488",
"class":"cell txt l",
"children":[
"Vulvodynia"
]
},
" ",
{
"type":"p",
"hlId":"6e3ba5",
"class":"cell txt l",
"children":[
"Ovarian cysts"
]
},
" ",
{
"type":"p",
"hlId":"33c742",
"class":"cell txt l",
"children":[
"Uterine myoma (fibroid)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd7d42",
"class":"col hd l",
"children":[
"Urologic Causes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1e05f",
"class":"cell txt l",
"children":[
"Interstitial cystitis/painful bladder syndrome"
]
},
" ",
{
"type":"p",
"hlId":"1bafbd",
"class":"cell txt l",
"children":[
"Radiation cystitis"
]
},
" ",
{
"type":"p",
"hlId":"89ca71",
"class":"cell txt l",
"children":[
"Urethral syndrome"
]
},
" ",
{
"type":"p",
"hlId":"748bee",
"class":"cell txt l",
"children":[
"Urinary calculi"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb60b9",
"class":"col hd l",
"children":[
"Gastrointestinal Causes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"521d73",
"class":"cell txt l",
"children":[
"Irritable bowel syndrome"
]
},
" ",
{
"type":"p",
"hlId":"271f14",
"class":"cell txt l",
"children":[
"Inflammatory bowel disease"
]
},
" ",
{
"type":"p",
"hlId":"a5cb00",
"class":"cell txt l",
"children":[
"Chronic constipation"
]
},
" ",
{
"type":"p",
"hlId":"41ee8c",
"class":"cell txt l",
"children":[
"Diverticulitis"
]
},
" ",
{
"type":"p",
"hlId":"6b2970",
"class":"cell txt l",
"children":[
"Celiac disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d66bd4",
"class":"col hd l",
"children":[
"Musculoskeletal/Neurologic Causes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eeede8",
"class":"cell txt l",
"children":[
"Myofascial pain syndromes"
]
},
" ",
{
"type":"p",
"hlId":"a24e07",
"class":"cell txt l",
"children":[
"Fibromyalgia"
]
},
" ",
{
"type":"p",
"hlId":"b48f10",
"class":"cell txt l",
"children":[
"Chronic coccygeal pain"
]
},
" ",
{
"type":"p",
"hlId":"a542dc",
"class":"cell txt l",
"children":[
"Chronic low back pain"
]
},
" ",
{
"type":"p",
"hlId":"ff404b",
"class":"cell txt l",
"children":[
"Piriformis syndrome"
]
},
" ",
{
"type":"p",
"hlId":"449e6f",
"class":"cell txt l",
"children":[
"Neuralgia"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_gm_t54":{
"id":"mk19_b_gm_t54",
"number":54,
"bookId":"gm2",
"title":{
"__html":"Clinical Presentation, Evaluation, and Management of Vaginitis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"eaa389",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 54. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t54"
}
]
},
"Clinical Presentation, Evaluation, and Management of Vaginitis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cd473",
"class":"col hd l",
"children":[
"Cause of Vaginitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f071b",
"class":"col hd l",
"children":[
"Clinical Presentation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b74a43",
"class":"col hd l",
"children":[
"Evaluation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe4dbc",
"class":"col hd l",
"children":[
"Management"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ab36a",
"class":"cell txt l",
"children":[
"Bacterial vaginosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24125a",
"class":"cell txt l",
"children":[
"Malodorous or “fishy” vaginal discharge"
]
},
" ",
{
"type":"p",
"hlId":"52b8f6",
"class":"cell txt l",
"children":[
"Increased thin white or gray discharge"
]
},
" ",
{
"type":"p",
"hlId":"daeb99",
"class":"cell txt l",
"children":[
"Symptoms other than malodor may be minimal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b778de",
"class":"cell txt l",
"children":[
"Diagnosis requires three of four findings (Amsel criteria):"
]
},
" ",
{
"type":"p",
"hlId":"43db8c",
"class":"cell txt li",
"children":[
"pH >4.5"
]
},
" ",
{
"type":"p",
"hlId":"798bac",
"class":"cell txt li",
"children":[
"Thin homogenous discharge"
]
},
" ",
{
"type":"p",
"hlId":"3b99a3",
"class":"cell txt li",
"children":[
"KOH amine whiff test result positive"
]
},
" ",
{
"type":"p",
"hlId":"ac4de0",
"class":"cell txt li",
"children":[
"Saline wet mount with >20% epithelial clue cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4edbc4",
"class":"cell txt l",
"children":[
"Metronidazole: 500 mg orally twice daily for 7 days",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" (avoid alcohol during treatment and for 24 hours after last dose); or vaginal gel (0.75%) 5 g into vagina at bedtime for 5 nights"
]
},
" ",
{
"type":"p",
"hlId":"6d0234",
"class":"cell txt l",
"children":[
"Clindamycin: vaginal cream (2%) 5 g into vagina for 7 nights"
]
},
" ",
{
"type":"p",
"hlId":"c2d098",
"class":"cell txt l",
"children":[
"Sexual partners do not require treatment"
]
},
" ",
{
"type":"p",
"hlId":"de5bdb",
"class":"cell txt l",
"children":[
"Avoid sexual activity (or use condoms) during treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bf376",
"class":"cell txt l",
"children":[
"Vulvovaginal candidiasis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a813d8",
"class":"cell txt l",
"children":[
"Itching, irritation, dysuria, dyspareunia, vulvodynia, excoriation, erythema, fissures"
]
},
" ",
{
"type":"p",
"hlId":"47ed8b",
"class":"cell txt l",
"children":[
"Increased thick white discharge"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd8a2f",
"class":"cell txt l",
"children":[
"pH ≤4.5"
]
},
" ",
{
"type":"p",
"hlId":"5de09a",
"class":"cell txt l",
"children":[
"KOH amine whiff test result negative"
]
},
" ",
{
"type":"p",
"hlId":"0c6579",
"class":"cell txt l",
"children":[
"KOH wet mount shows hyphae, pseudohyphae, or yeast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2fd931",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Uncomplicated",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"6e96f9",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Over-the-Counter Intravaginal Agents"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"44dd44",
"class":"cell txt l",
"children":[
"Clotrimazole: 1% cream 5 g intravaginally daily for 7–14 days; or 2% cream 5 g intravaginally daily for 3 days"
]
},
" ",
{
"type":"p",
"hlId":"ecba29",
"class":"cell txt l",
"children":[
"Miconazole: 2% cream 5 g intravaginally daily for 7 days; or 4% cream 5 g intravaginally daily for 3 days; or 100-mg vaginal suppository, one suppository daily for 7 days; or 200-mg vaginal suppository, one suppository for 3 days; or 1,200- mg vaginal suppository, one suppository for 1 day"
]
},
" ",
{
"type":"p",
"hlId":"c4eedf",
"class":"cell txt l",
"children":[
"Tioconazole: 6.5% ointment 5 g intravaginally in a single application"
]
},
" ",
{
"type":"p",
"hlId":"8193a5",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Prescription Intravaginal Agents"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"4ec40b",
"class":"cell txt l",
"children":[
"Butoconazole: 2% cream (single-dose bioadhesive product) 5 g intravaginally in a single application"
]
},
" ",
{
"type":"p",
"hlId":"7ec62e",
"class":"cell txt l",
"children":[
"Terconazole: 0.4% cream 5 g intravaginally daily for 7 days; or 0.8% cream 5 g intravaginally daily for 3 days; or 80-mg vaginal suppository, one suppository daily for 3 days"
]
},
" ",
{
"type":"p",
"hlId":"ed9663",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Prescription Oral Agent"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"ca8911",
"class":"cell txt l",
"children":[
"Fluconazole: 150 mg orally as a single dose"
]
},
" ",
{
"type":"p",
"hlId":"103d0b",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Complicated",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"ca8c85",
"class":"cell txt l",
"children":[
"Longer duration of initial oral or topical treatment, followed by maintenance therapy as needed:"
]
},
" ",
{
"type":"p",
"hlId":"617da6",
"class":"cell txt li",
"children":[
"Recurrent:"
]
},
" ",
{
"type":"p",
"hlId":"fa45c2",
"class":"cell txt lii",
"children":[
"Fluconazole: 150 mg orally every 3 days for a total of three doses; or topical imidazole therapy for 7-14 nights"
]
},
" ",
{
"type":"p",
"hlId":"67a3ba",
"class":"cell txt lii",
"children":[
"Maintenance therapy for refractory or recurrent symptoms:"
]
},
" ",
{
"type":"p",
"hlId":"fe4586",
"class":"cell txt lii",
"children":[
"Fluconazole: 150 mg orally weekly for 6 months"
]
},
" ",
{
"type":"p",
"hlId":"0bf52d",
"class":"cell txt li",
"children":[
"Severe:"
]
},
" ",
{
"type":"p",
"hlId":"225dd7",
"class":"cell txt lii",
"children":[
"Topical azole for 7-14 days or fluconazole 150mg for two doses separated by 72 hours"
]
},
" ",
{
"type":"p",
"hlId":"74477c",
"class":"cell txt li",
"children":[
"Non-albicans species:"
]
},
" ",
{
"type":"p",
"hlId":"517560",
"class":"cell txt lii",
"children":[
"Non-fluconazole topical azole for 7-14 days"
]
},
" ",
{
"type":"p",
"hlId":"cf424f",
"class":"cell txt l",
"children":[
"Pregnancy:"
]
},
" ",
{
"type":"p",
"hlId":"3a545d",
"class":"cell txt li",
"children":[
"Topical azole for 7 days; do not use fluconazole"
]
},
" ",
{
"type":"p",
"hlId":"c2d098",
"class":"cell txt l",
"children":[
"Sexual partners do not require treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44f3ef",
"class":"cell txt l",
"children":[
"Trichomoniasis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53b447",
"class":"cell txt l",
"children":[
"Increased discolored discharge (yellowish, green, gray, and/or frothy)"
]
},
" ",
{
"type":"p",
"hlId":"5aeade",
"class":"cell txt l",
"children":[
"Dyspareunia, dysuria, itch, erythema, postcoital bleeding"
]
},
" ",
{
"type":"p",
"hlId":"c2744a",
"class":"cell txt l",
"children":[
"Punctate cervical hemorrhages (“strawberry” cervix)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5de09a",
"class":"cell txt l",
"children":[
"KOH amine whiff test result negative"
]
},
" ",
{
"type":"p",
"hlId":"370c4c",
"class":"cell txt l",
"children":[
"Saline wet mount with trichomonads, leukocytes"
]
},
" ",
{
"type":"p",
"hlId":"375280",
"class":"cell txt l",
"children":[
"NAAT or rapid assay result positive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1cc00",
"class":"cell txt l",
"children":[
"Metronidazole",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
": 500 mg orally twice daily for 7 days"
]
},
" ",
{
"type":"p",
"hlId":"e9bd57",
"class":"cell txt l",
"children":[
"Treatment of sexual partners is recommended to prevent reinfection; for men, metronidazole 2 g orally as a single dose"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"KOH = potassium hydroxide; NAAT = nucleic acid amplification test."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Safe in pregnancy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Uncomplicated vulvovaginal candidiasis: ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida albicans"
]
},
", mild to moderate symptom severity, healthy nonpregnant women, one or two episodes per year."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Complicated vulvovaginal candidiasis: Recurrent (three or more episodes per year), severe symptoms, suspected or proven non-albicans ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" species, uncontrolled diabetes mellitus, or immunosuppression."
],
[
"Treatment regimens from the CDC Sexually Transmitted Infections Guidelines, 2021."
]
]
}
}
}